Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
IMMUTOL gene therapy shows promising cost-effectiveness at a value-based price up to approximately €500 000, contingent on achieving curative clinical efficacy. These findings inform strategic development and pricing considerations for emerging gene therapies in MS.
Authors
- Balàzs Nagy (ORCID: https://orcid.org/0000-0003-4125-7905)
- Rok Hren
- Attila Imre (ORCID: https://orcid.org/0009-0004-0110-8395)
Institutions
- Semmelweis University (HU)
- University of Ljubljana (SI)
- Institute of Mathematics, Physics, and Mechanics (SI)
- Syreon Research Institute (Hungary) (HU)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1002/bcp.70204
- Citations
- 2
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- European Commission
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap